<DOC>
	<DOCNO>NCT02366364</DOCNO>
	<brief_summary>The purpose study assess safety tolerability multiple oral ( PO ) ascend dose NRX-1074 normal healthy volunteer .</brief_summary>
	<brief_title>Study Safety , Tolerability Pharmacokinetics NRX-1074 Normal Healthy Volunteers</brief_title>
	<detailed_description>NRX-1074 N-methyl-D-aspartate ( NMDA ) receptor functional partial agonist efficacy animal model affective disorder include major depressive disorder . The purpose study evaluate safety tolerability multiple oral ( PO ) ascend dose NRX-1074 evidence incidence severity adverse event ( AEs ) , change serum chemistry , hematology , urinalysis , change physical examination finding , psychotomimetic finding subject-reported symptom .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Male female subject Aged 18 55 year For female subject , surgically sterile least 2 year menopausal , use acceptable method birth control . If childbearing potential , documented negative blood urine pregnancy test within 24 hour prior dose . Clinical laboratory value &lt; 2 time upper limit normal ( ULN ) deem clinically significant investigator Ability understand requirement study , provide write informed consent , abide study restriction , agree return require assessment Human immunodeficiency virus ( HIV ) infection , hepatitis ongoing infectious disease . Current evidence alcohol abuse ( great 4 unit alcohol day ; 1 unit = 1/2 pint beer , 1 glass wine 1 oz . spirit ) , option investigator subject may alcoholic . Current abuse illicit substance , use Diagnostic Statistical Manual ( DSM ) IV definition drug abuse . Current smoker use tobacco product . Currently pregnant , plan become pregnant course study , nurse mother . Type I Type II diabetes . Malignancy last 5 year , exception nonmetastatic basal cell squamous cell carcinoma skin localize carcinoma situ cervix . Currently take prescription overthecounter medication include herbal therapy , within 14 day enrollment study . History allergy , sensitivity , intolerance NMDAR ligands include ketamine , dextromethorphan , memantine , methadone , dextropropoxyphene , ketobemidone concomitant use agent . Received another investigational drug device within 30 day enrollment study . Previously participate study . Psychiatric disease include major depression , bipolar disorder , anxiety , schizophrenia , medical condition , opinion investigator , would interfere evaluation study drug safety . 13 ) In option Investigator Sponsor 's Study Monitor , history severe renal hepatic impairment , severe active hepatic disease , clinically significant medical condition may preclude safe study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>NRX-1074</keyword>
	<keyword>NMDA Receptor Modulator</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Glycine Site Modulator</keyword>
</DOC>